EGFR and non-small cell lung carcinoma: In the presence of EGFR oncogenic mutations, the use of EGFR tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of NSCLC and, at present, osimertinib, the third-generation EGFR-TKI, is the first-line therapy for NSCLC EGFR-mutated patients.